← Back to Search

Pentraxin

Zinpentraxin Alfa for Idiopathic Pulmonary Fibrosis (STARSCAPE-OLE Trial)

Phase 3
Waitlist Available
Research Sponsored by Hoffmann-La Roche
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from baseline until study completion (up to approximately 1.5 years)
Awards & highlights

Summary

This trial is testing a lab-made protein given through an IV to help reduce lung scarring and inflammation in patients with a chronic lung disease called idiopathic pulmonary fibrosis (IPF). The study includes patients who have already participated in related research.

Eligible Conditions
  • Idiopathic Pulmonary Fibrosis

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from baseline until study completion (up to approximately 1.5 years)
This trial's timeline: 3 weeks for screening, Varies for treatment, and from baseline until study completion (up to approximately 1.5 years) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Percentage of Participants With Adverse Events (AEs)
Percentage of Participants With Infusion Related Reactions (IRRs) and Other AEs of Special Interest
Percentage of of Participants Permanently Discontinuing Study Treatment Due to AEs
Secondary outcome measures
Annual Rate of Change in 6-Minute Walk Distance (6MWD)
Annual Rate of Change in FVC% Predicted
Annual Rate of Change in Forced Vital Capacity (FVC) (mL)
+8 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: Zinpentraxin AlfaExperimental Treatment1 Intervention
Corhort A: Participants entering, following participation in study PRM-151-202. Cohort B: Participants entering, following participation in study WA42293.

Find a Location

Who is running the clinical trial?

Hoffmann-La RocheLead Sponsor
2,436 Previous Clinical Trials
1,091,518 Total Patients Enrolled
16 Trials studying Idiopathic Pulmonary Fibrosis
4,442 Patients Enrolled for Idiopathic Pulmonary Fibrosis
Clinical TrialsStudy DirectorHoffmann-La Roche
2,204 Previous Clinical Trials
890,189 Total Patients Enrolled
16 Trials studying Idiopathic Pulmonary Fibrosis
4,677 Patients Enrolled for Idiopathic Pulmonary Fibrosis
~29 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top